GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mezagitamab   Click here for help

GtoPdb Ligand ID: 10609

Synonyms: TAK-079 | TAK079
Immunopharmacology Ligand
Compound class: Antibody
Comment: Mezagitamab (TAK-079) is a humanized, IgG1, cell-depleting anti-CD38 monoclonal antibody [7-8]. Anti-CD38 therapeutics were primarily developed as treatments for multiple myeloma [9], but have subsequently been discovered to offer potential in solid tumours and autoimmune diseases [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Chen H, Qiu Y, Yin Z, Wang Z, Tang Y, Ni H, Lu J, Chen Z, Kong Y, Wang Z. (2023)
Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis.
Front Immunol, 14: 1280226. [PMID:38022544]
2. Elias KA, Landes G, Singh S, Korver W, Drake AW, Haak-Frendscho M, Snell GP, Bhaskar V. (2012)
Anti-cd38 antibodies.
Patent number: WO2012092612A1. Assignee: Takeda Pharmaceutical Company Limited. Priority date: 30/12/2010. Publication date: 05/07/2012.
3. Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, Xia CQ, Smithson G, McLean L, Zalevsky J et al.. (2019)
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys.
J Pharmacol Exp Ther, 370 (2): 182-196. [PMID:31085699]
4. Krishnan AY, Patel KK, Mohan M, Jagannath S, Niesvizky R, Silbermann RW, Yu Z, Long T, McDonnell SRP, Berg D et al.. (2024)
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma.
Blood Neoplasia, 1 (4): 100043. [PMID:40552138]
5. Kuter DJ, Miura K, Patriarca A, Pulanić D, Radinoff A, Sapunarova K, Syrigou A, Yang R, Nguyen VA, Skelton E et al.. (2026)
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
N Engl J Med, 394 (14): 1388-1398. [PMID:41950473]
6. McDonnell SRP, Nguyen VA, Walton NM, Merkwirth C, Hong F, Berg D, Muensterman ET, Furie RA. (2024)
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
Lupus Sci Med, 11 (1). [PMID:38453421]
7. Roepcke S, Plock N, Yuan J, Fedyk ER, Lahu G, Zhao L, Smithson G. (2018)
Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial.
Pharmacol Res Perspect, 6 (3): e00402. [PMID:29864242]
8. Smithson G, Zalevsky J, Korver W, Roepcke S, Dahl M, Zhao L, Yuan J, McLean L, Elias K. (2017)
TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion.
Journal of Immunology, 198: 224.20.
9. van de Donk NWCJ, Usmani SZ. (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
Front Immunol, 9: 2134 eCollection. DOI: 10.3389/fimmu.2018.02134 [PMID:30294326]